<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38033705</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2059-8661</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Journal of clinical and translational science</Title><ISOAbbreviation>J Clin Transl Sci</ISOAbbreviation></Journal><ArticleTitle>Strategies used for the COVID-OUT decentralized trial of outpatient treatment of SARS-CoV-2.</ArticleTitle><Pagination><StartPage>e242</StartPage><MedlinePgn>e242</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e242</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1017/cts.2023.668</ELocationID><Abstract><AbstractText>The COVID-19 pandemic accelerated the development of decentralized clinical trials (DCT). DCT's are an important and pragmatic method for assessing health outcomes yet comprise only a minority of clinical trials, and few published methodologies exist. In this report, we detail the operational components of COVID-OUT, a decentralized, multicenter, quadruple-blinded, randomized trial that rapidly delivered study drugs nation-wide. The trial examined three medications (metformin, ivermectin, and fluvoxamine) as outpatient treatment of SARS-CoV-2 for their effectiveness in preventing severe or long COVID-19. Decentralized strategies included HIPAA-compliant electronic screening and consenting, prepacking investigational product to accelerate delivery after randomization, and remotely confirming participant-reported outcomes. Of the 1417 individuals with the intention-to-treat sample, the remote nature of the study caused an additional 94 participants to not take any doses of study drug. Therefore, 1323 participants were in the modified intention-to-treat sample, which was the a priori primary study sample. Only 1.4% of participants were lost to follow-up. Decentralized strategies facilitated the successful completion of the COVID-OUT trial without any in-person contact by expediting intervention delivery, expanding trial access geographically, limiting contagion exposure, and making it easy for participants to complete follow-up visits. Remotely completed consent and follow-up facilitated enrollment.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Avula</LastName><ForeName>Nandini</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5323-2639</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Medical School, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakach</LastName><ForeName>Dustin</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Investigational Drug Service, Fairview Health Services, University of Minnesota Medical Center, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tignanelli</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Medical School, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liebovitz</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicklas</LastName><ForeName>Jacinda M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-4418-5919</Identifier><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, University of Colorado-Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>UnitedHealth Group, Optum Health, Minnetonka, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puskarich</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, School of Medicine, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belani</LastName><ForeName>Hrishikesh K</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Department of Medicine, Olive View - University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buse</LastName><ForeName>John B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0002-9723-3876</Identifier><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klatt</LastName><ForeName>Nichole R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Surgery, Medical School, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Blake</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Atlanta Veterans Affairs Medical Center and the Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karger</LastName><ForeName>Amy B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartman</LastName><ForeName>Katrina M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Medical School, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Barkha</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medicine, Medical School, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fenno</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Medicine, Medical School, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Neha V</ForeName><Initials>NV</Initials><Identifier Source="ORCID">0000-0001-5327-2876</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Medical School, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erickson</LastName><ForeName>Spencer M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Medical School, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulware</LastName><ForeName>David R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-4715-0060</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Medical School, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bramante</LastName><ForeName>Carolyn T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Department of Medicine, Medical School, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVID-OUT Trial Team</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 DK124654</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK048520</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK124723</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Clin Transl Sci</MedlineTA><NlmUniqueID>101689953</NlmUniqueID><ISSNLinking>2059-8661</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Decentralized clinical trial</Keyword><Keyword MajorTopicYN="N">covid</Keyword><Keyword MajorTopicYN="N">randomized controlled trial</Keyword><Keyword MajorTopicYN="N">remote research</Keyword><Keyword MajorTopicYN="N">trial design</Keyword></KeywordList><CoiStatement>The fluvoxamine placebo tablets were donated by the Apotex pharmacy. The ivermectin placebo and active tablets were donated by the Edenbridge pharmacy. The funders had no influence on the design or conduct of the trial and were not involved in data collection or analysis, writing of the manuscript, or decision to submit for publication. The authors assume responsibility for trial fidelity and the accuracy and completeness of the data and analyses.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>30</Day><Hour>18</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>30</Day><Hour>18</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>30</Day><Hour>17</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38033705</ArticleId><ArticleId IdType="pmc">PMC10685265</ArticleId><ArticleId IdType="doi">10.1017/cts.2023.668</ArticleId><ArticleId IdType="pii">S2059866123006684</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mitchell EJ, Ahmed K, Breeman S, et al. It is unprecedented: trial management during the COVID-19 pandemic and beyond. Trials. 2020;21(1):784. doi: 10.1186/s13063-020-04711-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-020-04711-6</ArticleId><ArticleId IdType="pmc">PMC7484918</ArticleId><ArticleId IdType="pubmed">32917258</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue JZ, Smietana K, Poda P, Webster K, Yang G, Agrawal G. Clinical trial recovery from COVID-19 disruption. Nat Rev Drug Discov. 2020;19(10):662&#x2013;663. doi: 10.1038/d41573-020-00150-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-020-00150-9</ArticleId><ArticleId IdType="pubmed">32913212</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Buse JB, Liebovitz DM, et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023;23(10):1119&#x2013;1129. doi: 10.1016/S1473-3099(23)00299-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00299-2</ArticleId><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized trial of metformin, ivermectin, and fluvoxamine for covid-19. N Engl J Med. 2022;387(7):599&#x2013;610. doi: 10.1056/NEJMoa2201662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2201662</ArticleId><ArticleId IdType="pmc">PMC9945922</ArticleId><ArticleId IdType="pubmed">36070710</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19. N Engl J Med. 2020;383(6):517&#x2013;525. doi: 10.1056/NEJMoa2016638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2016638</ArticleId><ArticleId IdType="pmc">PMC7289276</ArticleId><ArticleId IdType="pubmed">32492293</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons LA, Phipps JE, Whipps M, et al. From hybrid to fully remote clinical trial amidst the COVID-19 pandemic: strategies to promote recruitment, retention, and engagement in a randomized mHealth trial. Digit Health. 2022;8:205520762211290. doi: 10.1177/20552076221129065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20552076221129065</ArticleId><ArticleId IdType="pmc">PMC9515527</ArticleId><ArticleId IdType="pubmed">36185388</ArticleId></ArticleIdList></Reference><Reference><Citation>Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Intern Med. 2020;173(8):623&#x2013;631. doi: 10.7326/M20-4207.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-4207</ArticleId><ArticleId IdType="pmc">PMC7384270</ArticleId><ArticleId IdType="pubmed">32673060</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjerpeseth LJ, Cesta CE, Furu K,et al. Metformin versus insulin and risk of major congenital malformations in pregnancies with Type 2 Diabetes: a nordic register-based cohort study. Diabetes Care. 2023;46(8):1556&#x2013;1564. doi: 10.2337/dc23-0256.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc23-0256</ArticleId><ArticleId IdType="pubmed">37343541</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarry-Adkins JL, Ozanne SE, Aiken CE. Impact of metformin treatment during pregnancy on maternal outcomes: a systematic review/meta-analysis. Sci Rep. 2021;11(1):9240. doi: 10.1038/s41598-021-88650-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-88650-5</ArticleId><ArticleId IdType="pmc">PMC8085032</ArticleId><ArticleId IdType="pubmed">33927270</ArticleId></ArticleIdList></Reference><Reference><Citation>
ClinCard Participant Support. greenphire.com. https://greenphire.com/participant-payments/clincard-participant-support/.
Accessed June 11, 2023.</Citation></Reference><Reference><Citation>
Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in
Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or
Treatment. Published online September 2020. https://www.fda.gov/media/142143/download. Accessed March 27,
2023.</Citation></Reference><Reference><Citation>Spiegel BMR, Hays RD, Bolus R, et al. Development of the NIH patient-reported outcomes measurement information system (PROMIS) gastrointestinal symptom scales. Am J Gastroenterol. 2014;109(11):1804&#x2013;1814. doi: 10.1038/ajg.2014.237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2014.237</ArticleId><ArticleId IdType="pmc">PMC4285435</ArticleId><ArticleId IdType="pubmed">25199473</ArticleId></ArticleIdList></Reference><Reference><Citation>
Pulse Oximeter Accuracy and Limitations: FDA Safety Communication.
Published online February 19, 2021. https://www.fda.gov/medical-devices/safety-communications/pulse-oximeter-accuracy-and-limitations-fda-safety-communication.
Accessed March 27, 2023.</Citation></Reference><Reference><Citation>Pocock SJ, Stone GW. The primary outcome fails &#x2014; what next? N Engl J Med. 2016;375(9):861&#x2013;870. doi: 10.1056/NEJMra1510064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1510064</ArticleId><ArticleId IdType="pubmed">27579636</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely EW, Ramanan AV, Kartman CE, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10(4):327&#x2013;336. doi: 10.1016/S2213-2600(22)00006-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00006-6</ArticleId><ArticleId IdType="pmc">PMC8813065</ArticleId><ArticleId IdType="pubmed">35123660</ArticleId></ArticleIdList></Reference><Reference><Citation>
Schuchat A, Walensky R. Agency Guidance Review. Published online March 10, 2021. https://stacks.cdc.gov/view/cdc/104139. Accessed March 27, 2023.</Citation></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl J Med. 2022;386(15):1397&#x2013;1408. doi: 10.1056/NEJMoa2118542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart J, Krows ML, Schaafsma TT, et al. Comparison of racial, ethnic, and geographic location diversity of participants enrolled in clinic-based vs 2 remote COVID-19 clinical trials. JAMA Netw Open. 2022;5(2):e2148325. doi: 10.1001/jamanetworkopen.2021.48325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.48325</ArticleId><ArticleId IdType="pmc">PMC8844998</ArticleId><ArticleId IdType="pubmed">35157053</ArticleId></ArticleIdList></Reference><Reference><Citation>Adepoju OE, Chae M, Ojinnaka CO, Shetty S, Angelocci T. Utilization gaps during the COVID-19 pandemic: racial and ethnic disparities in Telemedicine Uptake in federally qualified health center clinics. J Gen Intern Med. 2022;37(5):1191&#x2013;1197. doi: 10.1007/s11606-021-07304-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-021-07304-4</ArticleId><ArticleId IdType="pmc">PMC8809627</ArticleId><ArticleId IdType="pubmed">35112280</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiamulera C, Mantovani E, Tamburin S. Remote clinical trials: a timely opportunity for a virtual reality approach and its potential application in neurology. Br J Clin Pharmacol. 2021;87(10):3639&#x2013;3642. doi: 10.1111/bcp.14922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.14922</ArticleId><ArticleId IdType="pubmed">34041779</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahne J, Hawk LW. Health equity and decentralized trials. JAMA. 2023;329(23):2013&#x2013;2014. doi: 10.1001/jama.2023.6982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.6982</ArticleId><ArticleId IdType="pubmed">37261810</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>